Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01474382 · ClinicalTrials.gov registry record · Phase 4

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

A Phase 4 study of Anesthesia, Local and Dental Anesthesia, sponsored by Novocol Pharmaceutical of Canada.

Completed
Registry status
Phase 4
Development phase
150
Enrollment target
7
Study locations

NCT01474382: Completed Phase 4 study of Anesthesia, Local and Dental Anesthesia, sponsored by Novocol Pharmaceutical of Canada.

NCT01474382 is a Phase 4 study of Anesthesia, Local and Dental Anesthesia that has completed, run by Novocol Pharmaceutical of Canada. The registered enrollment target is 150 participants, above the 75-participant average among 18 other Anesthesia, Local trials with a reported enrollment target (100% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01474382, a Phase 4 study of Anesthesia, Local and Dental Anesthesia, has completed, sponsored by Novocol Pharmaceutical of Canada.

COMPLETED
Registry status
Phase 4
Development phase
150 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.

Interventions

  • OTHER Sham injection
  • DRUG OraVerse

Study Locations (7)

Pennsylvania

  • University of Pennsylvania School of Dental - Philadelphia
  • University of Pittsburgh School of Dental Medicine - Pittsburgh

California

  • University of California, San Francisco - San Francisco

Indiana

  • Indiana University School of Dentistry - Indianapolis

Ohio

  • Nationwide Children's Hospital - Columbus

Utah

  • Jean Brown Research - Salt Lake City

Washington

  • Center for Pediatric Dentistry - Seattle

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2012-02
Est. Completion 2014-08
Phase Phase 4
Novocol Pharmaceutical of Canada

1 total trials

What the finished NCT01474382 record still lists

NCT01474382 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 75-participant average among 18 other Anesthesia, Local trials with a reported enrollment target (100% higher).

The record links to 3 conditions, with Anesthesia, Local appearing as the primary indexed condition, and to 2 interventions - of which Sham injection is the first listed.

NCT01474382 lists 7 locations in 6 states (Pennsylvania, California, Indiana).

Frequently Asked Questions

What is clinical trial NCT01474382 about?

NCT01474382 is a clinical study titled "Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients". The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.

What is the current status of trial NCT01474382?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2012-02. Estimated completion is 2014-08.

What conditions does trial NCT01474382 study?

This clinical trial studies the following conditions: Anesthesia, Local, Dental Anesthesia, Anesthesia, Reversal.

What interventions are being tested in trial NCT01474382?

The interventions under investigation include: Sham injection (OTHER), OraVerse (DRUG).

Who is sponsoring clinical trial NCT01474382?

This trial is sponsored by Novocol Pharmaceutical of Canada, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01474382 being conducted?

This trial has 7 study locations across California, Indiana, Ohio, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anesthesia, Local

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01474382's enrollment target sits among peer trials

150 3rd of 18 higher than 16 of 18 other Anesthesia, Local trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anesthesia, Local trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01474382, the US trial registry maintained by the National Library of Medicine. NCT01474382 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.